Resistance to imatinib mesylate in chronic myeloid leukaemia.
about
Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemiaERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyForced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatmentTargeted treatment of chronic myeloid leukemia: role of imatinib.Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.Drug Repurposing for Cancer Therapy.ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cellsState-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.Bcr-Abl tyrosine kinase inhibitors: a patent review.Mechanisms of tumor cell resistance to the current targeted-therapy agents.Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase.Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.Antiproliferative effect of aaptamine on human chronic myeloid leukemia K562 cells.LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells.Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cellsHOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Imatinib mesylate resistance and mutations: An Indian experienceGuidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Platelet-derived growth factor receptors and ligands are up-regulated in paediatric fibromatosesModelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines
P2860
Q28474737-57B0DD6D-10E0-4C5D-AF3F-5A876543B859Q33476874-BFED7C16-159E-485C-84FB-7D19A76FCFDBQ33828409-4C085883-A6AF-462C-8DC2-6B6141C6B1C5Q33887799-F84A2BE0-C4D7-4655-AF42-C784569E55E2Q33915973-73EB0562-0659-4B5A-9F63-C562FD7BB950Q35032683-4C018446-5E5B-4957-A6B6-DF3C3CC5CCDCQ36229392-461C19AD-8EDE-4C13-80C3-9FC16284802AQ36353183-2D2B02A8-5B81-4678-B5A0-8E1DA7F7EEB4Q37141914-AE02F360-E42F-47BE-A066-CC130864B6F9Q37256808-A4792783-5D24-4583-B4BA-25127A664A65Q37376981-BE3A7660-74BF-4431-B01C-5BDA4815B212Q37657478-4A4C1EFB-6957-4624-9AF6-BF6BBFDFF441Q37709467-CCCEAD5F-68CB-499F-80CD-70ED4F25677EQ37781050-07020510-9E9B-4481-9C61-81B199228A02Q37836931-C76ADE7B-EE08-43F3-9EF4-9C1C2C5B6A7EQ38345974-08959AF7-29E5-4F91-8A73-5C433BB207BBQ38828353-8A85001E-8838-4D95-A868-0D9D0590B49BQ38923281-FAAF1ED3-EA4E-4F79-AC3F-8CBC45F5F45AQ38974040-101911E5-AEA6-4F7C-91F6-9D9A7AC3EDB9Q39355501-1A860C10-AD85-4628-B2EA-FDE78CF3749DQ39674644-B21193A1-07AF-4BD2-95D3-473D8A7578BBQ39700748-C7573668-A6D4-4B83-B973-25EFA1BD6DB9Q39917608-14E878B0-9FCE-409C-8B5A-C5495E142AC9Q41483822-1DCA3441-36C5-43B9-947A-F8E08881EC9FQ41673629-2B93E23A-E6CA-40D4-93DF-3A5E68599DA2Q41842515-901673E5-3E94-4AF4-A8EF-DEE10F875139Q41892319-1A8D58C2-D0E4-443F-93AE-11D1BD1C5A9DQ43971962-E66D04B5-8BA8-48D1-9AD1-3F05AA8A49CDQ44161665-17FB55A7-F630-4944-B213-79FBBF88C9B6Q47420917-CDED65B4-E398-4B70-9636-9D5C27E15811Q53670654-FC2F8716-910C-4EEA-A2A6-513A54D05F5AQ57522657-01FD0D3A-B723-40C9-83A1-B6C4D7C346BFQ58582644-10885DF3-92BA-4A40-9377-0A7F0579FC11
P2860
Resistance to imatinib mesylate in chronic myeloid leukaemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@ast
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@en
type
label
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@ast
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@en
prefLabel
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@ast
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@en
P1433
P1476
Resistance to imatinib mesylate in chronic myeloid leukaemia.
@en
P2093
Charles Chuah
Junia V Melo
P304
P356
10.1016/J.CANLET.2006.07.010
P407
P577
2006-09-01T00:00:00Z